Zacks analyst blog spotlights J&J, Pfizer, BioNTech and Moderna

0

For immediate release

Chicago, IL – March 21, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: J&J JNJ, Pfizer PFE, BioNTech BNTX and Moderna MRNA.

Here are highlights from Friday’s analyst blog:

What do J&J’s segments and pipeline have in store for us in 2022?

NOT A WORD‘s Pharmaceuticals segment is performing above the market despite currency headwinds and the impact of biosimilar and generic competition on sales of some key drugs like Remicade and Zytiga. Pharmaceuticals segment sales increased by 13.6% in 2021 on an organic basis despite the coronavirus pandemic. The increase in sales was led by J&J’s blockbuster drugs, Darzalex and Stelara and the contribution of new drugs, Erleada and Tremfya and its COVID-19 vaccine.

Meanwhile, other flagships like Simponi/Simponi Aria and Invega Sustenna are also contributing to the growth. J&J continues to expect its pharmaceuticals business to deliver market-leading sales growth in 2022, driven by drugs such as Darzalex, Tremfya, Stelara, Erleada and the new Rybrevant. J&J has a long-term goal to grow the pharmaceutical unit into a $60 billion segment by 2025.

Sales in the Consumer unit are improving, despite external supply constraints due to the availability of raw materials and the lack of manpower. These constraints hurt sales of the skin health and beauty franchise in the fourth quarter of 2021. J&J expects supply constraints to continue into 2022, with the majority of the impact expected in the first half, primarily in the skin health and beauty segments.

J&J began raising prices for its Consumer Health portfolio in 2022 due to the impact of inflationary pressure, including rising input costs. J&J expects price increases to keep it competitive in 2022.

In its medical device segment, the Omicron variant dampened recovery trends in medical and surgical procedures, particularly towards the end of the fourth quarter. The negative impact is expected to continue into the first half of 2022. However, J&J expects the market recovery to accelerate as the year progresses as global healthcare systems treat new patients and resolve issues. backlog of proceedings. The market recovery, coupled with the contribution from new product launches, should lead to better performance in the second half of 2022. J&J launched 20 major products in 2021.

Importantly, J&J’s single-shot COVID-19 vaccine has become a key revenue contributor. The vaccine was approved for emergency/conditional use in some countries in 2021 and vaccinations are in full swing. A booster shot of the vaccine was authorized for all adults in October 2021. The COVID-19 vaccine generated sales of approximately $2.4 billion in 2021.

Among other vaccine manufacturers, Pfizer and BioNTechThe FDA booster dose or “third dose” received emergency FDA approval in December for all adults 18 years and older, after completion of the primary vaccination with any COVID-19 vaccine FDA cleared or approved. Later, the EUA was extended to allow its use in individuals between 16 and 17 years of age, and then in adolescents between 12 and 15 years of age.

The Pfizer/BioNTech booster shot is the only one authorized for use in children under 18 years of age.

A booster dose of ModernSpikevax’s mRNA-based COVID-19 vaccine, Spikevax, has obtained an EUA for use in all adults in the United States at least six months after completion of the primary vaccination course with any licensed COVID-19 vaccine or FDA approved. In Europe, the booster dose of Moderna can be given at least three months after the second dose for people aged 18 and over. Meanwhile, pivotal studies are underway for the Omicron-specific booster candidate on Moderna.

J&J is also making rapid progress with its pipeline and line extensions. It won FDA approval for its BCMA-led CAR-T cell therapy, Carvykti (ciltacabtagene autoleucel) for previously treated relapsed or refractory multiple myeloma in February. An FDA decision on teclistamab for relapsed or refractory multiple myeloma and an EU decision on ciltacabtagene autoleucel are expected this year. Several pivotal data surveys are also expected in 2022.

J&J also plans to take a more aggressive stance on mergers and acquisitions activity, as it expects its strong cash position to help it pursue mergers and acquisitions to grow its business.

Why haven’t you watched Zacks best action?

Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.

See Free Stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

https://www.zacks.com

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. To visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.

Breakout biotech stocks with triple-digit profit potential

The biotechnology sector is expected to surpass $2.4 trillion by 2028, with scientists developing treatments for thousands of diseases. They are also finding ways to modify the human genome to literally erase our vulnerability to these diseases.

Zacks just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors take advantage of 7 stocks poised to outperform. Recommendations from previous editions of this report produced gains of +205%, +258% and +477%. Stocks in this report could perform even better.

See these 7 game-changing actions now >>

Click to get this free report

Johnson & Johnson (JNJ): Free Stock Analysis Report

Pfizer Inc. (PFE): Free Inventory Analysis Report

Moderna, Inc. (MRNA): Free Stock Analysis Report

ADR Sponsored by BioNTech SE (BNTX): Free Stock Analysis Report

To read this article on Zacks.com, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Share.

Comments are closed.